688382 益方生物-U
已收盘 07-03 15:00:00
资讯
新帖
简况
股市必读：益方生物（688382）登7月3日交易所龙虎榜
证券之星 · 01:17
股市必读：益方生物（688382）登7月3日交易所龙虎榜
7月3日益方生物（688382）龙虎榜数据：机构净买入1.22亿元，北向资金净卖出7665.08万元
证券之星 · 07-03 17:44
7月3日益方生物（688382）龙虎榜数据：机构净买入1.22亿元，北向资金净卖出7665.08万元
益方生物（688382）披露关于变更公司注册资本并修订《公司章程》的公告，7月2日股价上涨4.79%
证券之星 · 07-02
益方生物（688382）披露关于变更公司注册资本并修订《公司章程》的公告，7月2日股价上涨4.79%
新股消息 | 益方生物(688382.SH)港股IPO招股书失效
智通财经 · 07-02
新股消息 | 益方生物(688382.SH)港股IPO招股书失效
每周股票复盘：益方生物（688382）授出657.0981万股限售股
证券之星 · 06-28
每周股票复盘：益方生物（688382）授出657.0981万股限售股
益方生物（688382）发布向2026年限制性股票激励计划激励对象授予限制性股票的公告，6月24日股价上涨3.02%
证券之星 · 06-24
益方生物（688382）发布向2026年限制性股票激励计划激励对象授予限制性股票的公告，6月24日股价上涨3.02%
每周股票复盘：益方生物（688382）2026年限制性股票激励计划获通过
证券之星 · 06-20
每周股票复盘：益方生物（688382）2026年限制性股票激励计划获通过
益方生物（688382）披露2025年年度股东会决议公告，6月18日股价上涨2.81%
证券之星 · 06-18
益方生物（688382）披露2025年年度股东会决议公告，6月18日股价上涨2.81%
每周股票复盘：益方生物（688382）新增1,243,513股上市
证券之星 · 06-07
每周股票复盘：益方生物（688382）新增1,243,513股上市
益方生物（688382）披露限制性股票激励计划归属结果暨股票上市公告，6月1日股价下跌4.15%
证券之星 · 06-01
益方生物（688382）披露限制性股票激励计划归属结果暨股票上市公告，6月1日股价下跌4.15%
益方生物(688382.SH)拟推2026年限制性股票激励计划
智通财经 · 05-28
益方生物(688382.SH)拟推2026年限制性股票激励计划
每周股票复盘：益方生物（688382）一季度收入增419.51%
证券之星 · 05-02
每周股票复盘：益方生物（688382）一季度收入增419.51%
益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元
智通财经 · 04-28
益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元
图解益方生物一季报：第一季度单季净利润同比增长22.84%
证券之星 · 04-28
图解益方生物一季报：第一季度单季净利润同比增长22.84%
长城国瑞证券：给予益方生物买入评级
证券之星 · 04-22
长城国瑞证券：给予益方生物买入评级
4月22日益方生物涨9.09%，平安匠心优选混合A基金重仓该股
证券之星 · 04-22
4月22日益方生物涨9.09%，平安匠心优选混合A基金重仓该股
益方生物（688382）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月15日股价上涨0.47%
证券之星 · 04-15
益方生物（688382）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月15日股价上涨0.47%
每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜
证券之星 · 04-05
每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜
4月1日益方生物（688382）龙虎榜数据：机构净买入6154.66万元，北向资金净买入1469.8万元
证券之星 · 04-01
4月1日益方生物（688382）龙虎榜数据：机构净买入6154.66万元，北向资金净买入1469.8万元
每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组
证券之星 · 03-29
每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组
加载更多
公司概况
公司名称：
益方生物科技(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-25
主营业务：
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是技术授权、技术合作。截至报告期末，公司新申请发明专利85项，累计获得境内外发明专利授权157项。
发行价格：
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物-U","latestPrice":22.76,"timestamp":1783062000000,"preClose":21.43,"halted":0,"volume":29688181,"delay":0,"changeRate":0.0621,"floatShares":580000000,"shares":580000000,"eps":-0.5241,"marketStatus":"已收盘","change":1.33,"latestTime":"07-03 15:00:00","open":22.17,"high":23.15,"low":21.41,"amount":661000000,"amplitude":0.0812,"askPrice":22.76,"askSize":195,"bidPrice":22.75,"bidSize":168,"shortable":0,"etf":0,"ttmEps":-0.5241,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.43,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":23.57,"lowLimit":19.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":579592004,"isCdr":false,"pbRate":8.82,"roa":"--","roe":"--","epsLYR":-0.5479,"committee":-0.452935,"marketValue":13192000000,"turnoverRate":0.0512,"status":0,"afterMarket":{"amount":32546.8,"volume":1430,"close":22.76,"buyVolume":3370,"sellVolume":0,"time":1783064037746,"indexStatus":"已收盘 07-03 15:30:00","preClose":21.43},"floatMarketCap":13192000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2649615001","title":"股市必读：益方生物（688382）登7月3日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649615001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649615001?lang=zh_cn&edition=full","pubTime":"2026-07-06 01:17","pubTimestamp":1783271828,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，益方生物报收于22.76元，上涨6.21%，换手率5.12%，成交量29.69万手，成交额6.61亿元。龙虎榜上榜益方生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%，于2026年7月3日登上沪深交易所龙虎榜；此次为近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600000440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648650998","title":"7月3日益方生物（688382）龙虎榜数据：机构净买入1.22亿元，北向资金净卖出7665.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648650998","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648650998?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:44","pubTimestamp":1783071878,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月3日公布的交易公开信息显示，益方生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月3日收盘，益方生物报收于22.76元，上涨6.21%，换手率5.12%，成交量29.69万手，成交额6.61亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入1.22亿元，北向资金合计净卖出7665.08万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300032993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685030","title":"益方生物（688382）披露关于变更公司注册资本并修订《公司章程》的公告，7月2日股价上涨4.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685030","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648685030?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:24","pubTimestamp":1783002259,"startTime":"0","endTime":"0","summary":"近日，益方生物科技（上海）股份有限公司发布《关于变更公司注册资本并修订〈公司章程〉的公告》。公告显示，公司于2026年6月30日召开第二届董事会2026年第八次会议，审议通过变更注册资本并修订《公司章程》的议案。因2022年限制性股票激励计划部分股份完成归属，公司股本总数由578,348,491股增至579,592,004股，注册资本由578,348,491元增至579,592,004元。《公司章程》第六条和第二十二条相应修订，其他条款不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648799524","title":"新股消息 | 益方生物(688382.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2648799524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648799524?lang=zh_cn&edition=full","pubTime":"2026-07-02 06:41","pubTimestamp":1782945678,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，益方生物科技(上海)股份有限公司于2026年1月1日所递交的港股招股书满6个月，于2026年7月1日失效，中信证券为其独家保荐人。据此前招股书，益方生物是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK0239","688382","BK4588","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646916313","title":"每周股票复盘：益方生物（688382）授出657.0981万股限售股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646916313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646916313?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:14","pubTimestamp":1782584053,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，益方生物报收于15.96元，较上周的17.19元下跌7.16%。本周关注点公司公告汇总：益方生物向183名激励对象授出657.0981万股限制性股票，授予价格为10.55元/股。因1名激励对象离职，激励对象人数由184人调整为183人，限制性股票总量657.0981万股保持不变。其中，董事、财务总监史陆伟获授50.1952万股，占授予总数的7.64%；182名骨干人员合计获授606.9029万股，占授予总数的92.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645081954","title":"益方生物（688382）发布向2026年限制性股票激励计划激励对象授予限制性股票的公告，6月24日股价上涨3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645081954","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645081954?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:15","pubTimestamp":1782310517,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，益方生物报收于17.4元，较前一交易日上涨3.02%，最新总市值为100.85亿元。近日，益方生物科技（上海）股份有限公司发布《关于向2026年限制性股票激励计划激励对象授予限制性股票的公告》。本次授予的限制性股票将在授予日起12个月后分三期归属，归属比例分别为40%、40%、20%。该激励计划有效期最长不超过60个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400043838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063712","title":"每周股票复盘：益方生物（688382）2026年限制性股票激励计划获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063712","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063712?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:33","pubTimestamp":1781893989,"startTime":"0","endTime":"0","summary":"本次股东会于2026年6月18日以现场与网络投票相结合的方式召开，审议通过了董事会工作报告、年度报告、利润分配方案、董事及高管薪酬、限制性股票激励计划等议案。关于公司2026年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告指出，在自查期间，共有2名内幕信息知情人存在买卖公司股票的行为，其交易系基于公开信息和个人判断作出，不存在利用内幕信息进行交易的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644846670","title":"益方生物（688382）披露2025年年度股东会决议公告，6月18日股价上涨2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644846670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644846670?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:34","pubTimestamp":1781793259,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，益方生物报收于17.19元，较前一交易日上涨2.81%，最新总市值为99.63亿元。该股当日开盘16.6元，最高17.62元，最低16.4元，成交额达2.24亿元，换手率为2.26%。近日，益方生物科技（上海）股份有限公司发布《2025年年度股东会决议公告》。会议表决程序合法有效，无被否决议案。关联股东对相关议案回避表决，中小投资者对多项议案单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800042676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127878","title":"每周股票复盘：益方生物（688382）新增1,243,513股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127878?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:04","pubTimestamp":1780769053,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，益方生物报收于17.59元，较上周的19.5元下跌9.79%。益方生物当前最新总市值101.95亿元，在化学制药板块市值排名47/150，在两市A股市值排名1919/5206。本次归属新增股份1,243,513股，上市流通日为2026年6月5日，股票来源为公司向激励对象定向发行A股普通股。归属完成后公司总股本增至579,592,004股，控股股东持股比例未发生变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640950233","title":"益方生物（688382）披露限制性股票激励计划归属结果暨股票上市公告，6月1日股价下跌4.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640950233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640950233?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:35","pubTimestamp":1780324516,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，益方生物报收于18.69元，较前一交易日下跌4.15%，最新总市值为108.09亿元。公告显示，公司已完成2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分（第二批）第二个归属期的股份登记工作。本次归属新增股份1,243,513股，上市流通日为2026年6月5日，股票来源为公司向激励对象定向发行A股普通股。本次归属后公司总股本增至579,592,004股，控股股东持股比例未发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100041257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638466093","title":"益方生物(688382.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2638466093","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638466093?lang=zh_cn&edition=full","pubTime":"2026-05-28 19:23","pubTimestamp":1779967380,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)披露2026年限制性股票激励计划(草案)，拟授予激励对象的限制性股票数量为657.0981万股，约占激励计划草案公布日公司股本总额的1.14%。本次授予为一次性授予，无预留权益。激励计划涉及的激励对象共计184人，授予价格为10.55元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632562833","title":"每周股票复盘：益方生物（688382）一季度收入增419.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632562833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632562833?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:13","pubTimestamp":1777669992,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，益方生物报收于23.3元，较上周的22.28元上涨4.58%。本周，益方生物4月30日盘中最高价报24.05元。业绩披露要点：2026年一季度主营收入4254.24万元，同比上升419.51%。股本股东变化股东户数变动截至2026年3月31日，益方生物股东户数为1.77万户，较2025年12月31日增加2825.0户，增幅18.96%。户均持股数量由上期的3.88万股降至3.26万股，户均持股市值为62.06万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630558638","title":"益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630558638","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630558638?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:45","pubTimestamp":1777387551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)披露2026年第一季度报告，报告期公司实现营收4254万元，同比增长419.51%;归母净利润亏损4437万元;扣非净利润亏损4545万元。基本每股收益-0.08元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630089273","title":"图解益方生物一季报：第一季度单季净利润同比增长22.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630089273","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630089273?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:43","pubTimestamp":1777373004,"startTime":"0","endTime":"0","summary":"证券之星消息，益方生物2026年一季报显示，一季度公司主营收入4254.24万元，同比上升419.51%；归母净利润-4436.72万元，同比上升22.84%；扣非净利润-4545.15万元，同比上升21.93%；负债率6.58%，财务费用-443.0万元，毛利率96.17%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048348","title":"长城国瑞证券：给予益方生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629048348?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:07","pubTimestamp":1776856055,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦,魏钰琪近期对益方生物进行研究并发布了研究报告《业绩受授权合作收入确认扰动 看好TYK2自免产品BIC潜力》，给予益方生物买入评级。 事件点评： 公司 2025 年业绩承压源于授权收入确认节奏波动。格索雷塞已于 2024 年 11 月获 NMPA 批准上市， 用于治疗至少接受过一种系统性治疗的 KRASG12C 突变型的晚期非小细胞肺癌 成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200046407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015115","title":"4月22日益方生物涨9.09%，平安匠心优选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629015115?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:29","pubTimestamp":1776846569,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日益方生物涨9.09%，收盘报23.28元，换手率4.54%，成交量26.24万手，成交额5.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共27家，其中持有数量最多的公募基金为平安基金的平安匠心优选混合A。平安匠心优选混合A目前规模为21.21亿元，最新净值1.6219，较上一交易日下跌0.09%，近一年上涨46.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627840764","title":"益方生物（688382）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月15日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627840764","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627840764?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:07","pubTimestamp":1776244050,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，益方生物报收于21.27元，较前一交易日上涨0.47%，最新总市值为123.01亿元。该股当日开盘21.77元，最高22.2元，最低20.44元，成交额达4.98亿元，换手率为4.08%。本次授权尚需提交公司2025年年度股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616272","title":"每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616272?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:31","pubTimestamp":1775327469,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，益方生物报收于22.8元，较上周的19.99元上涨14.06%。本周，益方生物4月2日盘中最高价报23.96元。3月31日盘中最低价报18.94元。益方生物当前最新总市值131.86亿元，在化学制药板块市值排名43/150，在两市A股市值排名1471/5193。本周关注点交易信息汇总：益方生物因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624759945","title":"4月1日益方生物（688382）龙虎榜数据：机构净买入6154.66万元，北向资金净买入1469.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624759945","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624759945?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035270,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，益方生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘，益方生物报收于22.08元，上涨16.09%，换手率6.59%，成交量38.12万手，成交额8.11亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入6154.66万元，北向资金合计净买入1469.8万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623096387","title":"每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2623096387","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623096387?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:38","pubTimestamp":1774719490,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，益方生物报收于19.99元，较上周的17.68元上涨13.07%。本周关注点来自公司公告汇总：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组。来自公司公告汇总：益方生物终止2025年限制性股票激励计划，因市场环境及股价波动影响。公司公告汇总益方生物自愿披露，其自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病的注册性III期临床试验已完成全部受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783290451272,"stockEarnings":[{"period":"1week","weight":0.4261},{"period":"1month","weight":0.2851},{"period":"3month","weight":-0.0018},{"period":"6month","weight":-0.1645},{"period":"1year","weight":-0.3101},{"period":"ytd","weight":-0.1645}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17726人(较上一季度增加18.96%)","perCapita":"32697股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57959万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是技术授权、技术合作。截至报告期末，公司新申请发明专利85项，累计获得境内外发明专利授权157项。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物-U,688382,益方生物-U股票,益方生物-U股票老虎,益方生物-U股票老虎国际,益方生物-U行情,益方生物-U股票行情,益方生物-U股价,益方生物-U股市,益方生物-U股票价格,益方生物-U股票交易,益方生物-U股票购买,益方生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}